Celon Pharma S.A. is a European biopharmaceutical company focused on the discovery and clinical-stage development of innovative therapies addressing high unmet needs in neuropsychiatry, metabolic diseases, inflammation/autoimmunity, and oncology. We combine strong translational science with efficient clinical execution to advance differentiated assets from discovery to proof-of-concept and beyond.

Our approach

• Differentiated innovation: we develop first- and best-in-class programs across small molecules and advanced biologics (including mRNA, bispecifics/antibody-based modalities), selecting targets and indications where we can deliver meaningful clinical benefit.
• Capital-efficient development: we fund innovation through a dual engine: revenue from an established generics business and substantial non-dilutive European Union grants, enabling focused, disciplined progression of our pipeline.